We aimed to evaluate the efficacy and safety of ixekizumab (IL-17 inhibitor), low-dose IL-2, and colchicine (indirect IL-6 inhibitor) combined with SOC treatment in comparison with SOC alone for the treatment of hospitalized patients with moderate-to-critical COVID-19. The gene discussed is IL2; the disease is COVID-19.